BACLOFEN by Slayback Pharma LLC / Bora Pharmaceutical Services Inc BACLOFEN suspension

BACLOFEN by

Drug Labeling and Warnings

BACLOFEN by is a Prescription medication manufactured, distributed, or labeled by Slayback Pharma LLC, Bora Pharmaceutical Services Inc. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS & USAGE

    Baclofen oral suspension is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.

    Baclofen oral suspension may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

    Limitations of Use

    Baclofen oral suspension is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.

  • 2 DOSAGE & ADMINISTRATION

    2.1 Important Information

    Baclofen oral suspension is a concentrated formulation. Verify the strength and the dose of the product prior to prescribing, dispensing, and administering.

    2.2 Recommended Dosage

    Initiate baclofen oral suspension with a low dosage, preferably in divided doses, administered orally. The following gradually increasing dosage regimen is suggested, but should be adjusted based on clinical response and tolerability:

    1 mL (5 mg) three times a day for three days
    2 mL (10 mg) three times a day for three days
    3 mL (15 mg) three times a day for three days 
    4 mL (20 mg) three times a day for three days

    Additional increases may be necessary up to the maximum recommended dosage of 80 mg daily [4 mL (20 mg) four times a day].

    2.3 Administration Instructions

    Shake well baclofen oral suspension before administration. Discard unused portion 2 months after first opening.

    A calibrated measuring device is recommended to measure and deliver the prescribed dose accurately. A household teaspoon or tablespoon is not an adequate measuring device.


    2.4 Discontinuation of baclofen oral suspension

    When discontinuing baclofen oral suspension, reduce the dosage slowly and avoid abrupt withdrawn from the drug to help minimize the risk of adverse reactions [see Warnings and Precautions (5.1)].

  • 3 DOSAGE FORMS & STRENGTHS

    Oral Suspension: 25 mg per 5 mL (5 mg/mL) baclofen as a concentrated white to off white, grape-flavored suspension.

  • 4 CONTRAINDICATIONS

    Baclofen oral suspension is contraindicated in patients with hypersensitivity to baclofen.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Adverse Reactions from Abrupt Withdrawal of baclofen oral suspension

    Abrupt discontinuation of baclofen, regardless of the cause, has resulted in adverse reactions that include hallucinations, seizures, high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure, and death. Therefore, reduce the dosage slowly when baclofen oral suspension is discontinued, unless the clinical situation justifies a rapid withdrawal.

    5.2 Neonatal Withdrawal Symptoms

    Withdrawal symptoms in neonates whose mothers were treated with oral baclofen throughout pregnancy have been reported starting hours to days after delivery. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure. If the potential benefit justifies the potential risk to the fetus and baclofen oral suspension is continued during pregnancy, gradually reduce the dosage and discontinue baclofen oral suspension before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the exposed neonate of the potential for neonatal withdrawal.

    5.3 Drowsiness and Sedation

    Drowsiness and sedation have been reported in up to 63% of patients taking baclofen, the active ingredient in baclofen oral suspension [see Adverse Reactions (6.1)]. Patients should avoid operation of automobiles or other dangerous machinery and activities made hazardous by decreased alertness when starting baclofen oral suspension or increasing the dose until they know how the drug affects them.
    Advise patients that the central nervous system depressant effects of baclofen oral suspension may be additive to those of alcohol and other CNS depressants.

    5.4 Poor Tolerability in Stroke Patients

    Baclofen oral suspension should be used with caution in patients who have had a stroke. Baclofen has not significantly benefited patients with stroke. These patients have also shown poor tolerability to the drug.

    5.5 Exacerbation of Psychotic Disorders, Schizophrenia, or Confusional States

    Baclofen oral suspension should be used with caution in patients suffering from psychotic disorders, schizophrenia, or confusional states. If treated with baclofen oral suspension, these patients should be kept under careful surveillance because exacerbations of these conditions have been observed with oral baclofen administration.

    5.6 Exacerbation of Autonomic Dysreflexia

    Baclofen oral suspension should be used with caution in patients with a history of autonomic dysreflexia. The presence of nociceptive stimuli or abrupt withdrawal of baclofen oral suspension may cause an autonomic dysreflexic episode.

    5.7 Exacerbation of Epilepsy

    Baclofen oral suspension should be used with caution in patients with epilepsy. Deterioration in seizure control has been reported in patients taking baclofen.

    5.8 Posture and Balance Effects

    Baclofen oral suspension should be used with caution in patients where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain increased function.

    5.9 Ovarian Cysts

    A dose-related increase in incidence of ovarian cysts was observed in female rats treated chronically with oral baclofen. Ovarian cysts have been found by palpation in about 4% of the multiple sclerosis patients who were treated with oral baclofen for up to one year. In most cases, these cysts disappeared spontaneously while patients continued to receive the drug. Ovarian cysts are estimated to occur spontaneously in approximately 1% to 5% of the normal female population.

  • 6 ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in the labeling:

     Adverse Reactions from Abrupt Withdrawal of baclofen oral suspension [see Warnings and Precautions (5.1)]
     Neonatal Withdrawal Symptoms [see Warnings and Precautions (5.2)]
     Drowsiness and Sedation [see Warnings and Precautions (5.3)]
     Poor Tolerability in Stroke Patients [see Warnings and Precautions (5.4)]
     Exacerbation of Psychotic Disorders, Schizophrenia, or Confusional States [see Warnings and Precautions (5.5)]
     Exacerbation of Autonomic Dysreflexia [see Warnings and Precautions (5.6)]
     Exacerbation of Epilepsy [see Warnings and Precautions (5.7)]
     Posture and Balance Effects [see Warnings and Precautions (5.8)]
     Ovarian Cysts [see Warnings and Precautions (5.9)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The most common adverse reaction is transient drowsiness. In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions (up to 15%) are dizziness and weakness. Adverse reactions with a frequency of ≥1% are listed in Table 1.


    Table 1. Common (≥1%) Adverse Reactions in Patients Treated with baclofen for Spasticity

    ADVERSE REACTION
    		PERCENT
    Drowsiness
    		10-63%
    Dizziness
    		5-15%
    Weakness
    		5-15%
    Nausea
    		4-12%
    Confusion
    		1-11%
    Hypotension
    		0-9%
    Headache
    		4-8%
    Insomnia
    		2-7%
    Constipation
    		2-6%
    Urinary Frequency
    		2-6%
    Fatigue
    		2-4%

    The following adverse reactions not included in Table 1, classified by body system, were also reported:

    Neuropsychiatric: euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure

    Cardiovascular: dyspnea, palpitation, chest pain, syncope

    Gastrointestinal: dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool

    Genitourinary: enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria

    Other: rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion

    The following laboratory tests have been found to be abnormal in patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar.

  • 7 DRUG INTERACTIONS

    7.1 CNS Depressants and Alcohol

    Baclofen oral suspension can cause CNS depression, including drowsiness and sedation, which may be additive when used concomitantly with other CNS depressants or alcohol [see Warnings and Precautions (5.3)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no adequate data on the risk of major birth defects, miscarriages, or other maternal adverse outcomes associated with the use of baclofen oral suspension in pregnant women. There are adverse effects on fetal outcomes associated with withdrawal from baclofen after delivery (see Clinical Considerations). Oral administration of baclofen to pregnant rats resulted in an increased incidence of fetal structural abnormalities at a dose that was also associated with maternal toxicity. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    Clinical Considerations

    Fetal/Neonatal Adverse Reactions

    Baclofen oral suspension may increase the risk of late-onset neonatal withdrawal symptoms [see Warnings and Precautions (5.2)].

    Data

    Animal Data

    Baclofen given orally has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times on a mg/kg basis, or 3 times on a mg/m2 basis, the maximum oral dose recommended for human use; this dose also caused reductions in food intake and weight gain in the dams. This abnormality was not seen in mice or rabbits.

    8.2 Lactation

    Risk Summary

    At recommended oral doses, baclofen is present in human milk. There are no human data on the effects of baclofen on milk production. Withdrawal symptoms can occur in breastfed infants when maternal administration of baclofen oral suspension is stopped, or when breastfeeding is stopped [see Warnings and Precautions (5.2)]. There are no adequate data on other effects of baclofen on the breastfed infant.

    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for baclofen oral suspension and any potential adverse effects on the breastfed infant from baclofen oral suspension or from the underlying maternal condition.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients below the age of 12 have not been established.

    8.5 Geriatric Use

    In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Use in Specific Populations (8.6)].

    8.6 Renal Impairment

    Because baclofen is primarily excreted unchanged through the kidneys, baclofen oral suspension should be given with caution to patients with renal impairment, and it may be necessary to reduce the dosage.

  • 10 OVERDOSAGE

    10.1 Symptoms of baclofen Overdose

    With overdose of baclofen, patients may present in coma or with progressive drowsiness, lightheadedness, dizziness, somnolence, accommodation disorders, respiratory depression, seizures, or hypotonia progressing to loss of consciousness.

    10.2 Treatment for Overdose

    The treatment of baclofen overdose includes gastric decontamination, maintaining an adequate airway and respirations.

  • 11 DESCRIPTION

    Baclofen oral suspension is a gamma-aminobutyric acid (GABA-ergic) agonist available as 25 mg per 5 mL (5 mg/mL) suspension for oral administration. Its chemical name is 4-amino-3-(4-chlorophenyl)-butanoic acid, and its structural formula is:


    Baclofen structure


    Molecular formula is C10H12CINO2.
    Molecular Weight is 213.66 g/mol.

    Baclofen USP is a white to off-white, odorless or practically odorless crystalline powder. It is slightly soluble in water, very slightly soluble in methanol, and insoluble in chloroform.

    The baclofen oral suspension inactive ingredients are artificial grape flavor, hydrochloric acid, hypromellose, methyl paraben, propyl paraben, purified water, simethicone emulsion, sodium hydroxide, sucralose and xanthan gum.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The precise mechanism of action of baclofen is not fully understood. Baclofen inhibits both monosynaptic and polysynaptic reflexes at the spinal level, possibly by decreasing excitatory neurotransmitter release from afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Baclofen is a structural analog of the inhibitory neurotransmitter gamma- aminobutyric acid (GABA) and may exert its effects by stimulation of the GABAB receptor subtype.

    12.2 Pharmacodynamics

    Baclofen has been shown to have general CNS depressant properties, as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression [see Warnings and Precautions (5.3), Adverse Reactions (6.1), and Overdosage (10.1)].

    12.3 Pharmacokinetics

    A pharmacokinetic study in heathy adult male and female subjects under fasting conditions at 20 mg dose level demonstrated similar bioavailability for baclofen oral suspension and oral tablets.

    Absorption

    The peak plasma concentrations of baclofen were achieved in about 1 hour from administration of baclofen oral suspension in the fasted state, and the apparent elimination half-life is about 5.6 hours.

    Effect of Food
    Administration of baclofen oral suspension with a high-fat meal resulted in 9% decrease in AUC and 33% decrease in Cmax compared to the fasted state.

    Elimination

    Baclofen is excreted primarily by the kidney in unchanged form, and there is relatively large intersubject variation in absorption and/or elimination.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis & Mutagenesis & Impairment Of Fertility

    Carcinogenesis

    No increase in tumors was seen in rats receiving baclofen orally for two years at approximately 30 to 60 times on a mg/kg basis, or 10 to 20 times on a mg/m2 basis, the maximum oral dose recommended for human use.

    Mutagenesis

    Genetic toxicology assays have not been conducted for baclofen.

    Impairment of Fertility


    Studies to evaluate the effects of baclofen on fertility have not been conducted.

  • 14 CLINICAL STUDIES

    The efficacy of baclofen oral suspension is based upon a bioavailability study in healthy adults comparing baclofen oral tablets to baclofen oral suspension [see Clinical Pharmacology (12.3)].

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    Baclofen oral suspension contains 25 mg per 5 mL (5 mg/mL) baclofen. It is a white to off white viscous suspension and is supplied in high-density polyethylene (HDPE) bottles with white, polypropylene, child-resistant closures with a foam liner and tamper evident band.

    250 mL, NDC: 71225-140-01

    16.2 Storage and Handling

    Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° and 30° (59° and 86° F) (see USP Controlled Room Temperature).

    Discard unused portion 2 months after first opening.


  • 17 PATIENT COUNSELING INFORMATION

    Administration Instructions

    Inform patients that baclofen oral suspension is a concentrated formulation. Instruct patients or caregivers to use an oral dosing syringe and not to use a household teaspoon to correctly measure the prescribed amount of medication. Inform patients that oral dosing syringes may be obtained from their pharmacy. Instruct patients to shake before using [see Dosage and Administration (2.1, 2.3)].

    Risks Related to Sudden Withdrawal of baclofen oral suspension

    Advise patients and caregivers not to discontinue use of baclofen oral suspension without consulting with their healthcare provider because sudden withdrawal of baclofen oral suspension can result in serious complications that include hallucinations, seizures, high fever, confusion, muscle stiffness, multiple organ-system failure, and death [see Warnings and Precautions (5.1)]. Inform patients that early symptoms of baclofen oral suspension withdrawal may include increased spasticity, itching, and tingling of extremities.

    Neonatal Withdrawal Symptoms

    Advise patients to notify their healthcare provider if they are pregnant, plan to become pregnant, or plan to breastfeed [see Warnings and Precautions (5.2) and Use in Specific Populations (8.2)].

    Increased Risk of Drowsiness with Alcohol and Other CNS Depressants

    Advise patients that baclofen oral suspension may cause drowsiness, and that they should avoid the operation of automobiles or other dangerous machinery, or activities made hazardous by decreased alertness when starting baclofen oral suspension or increasing the dose until they know how the drug affects them [see Warnings and Precautions (5.3)]. Inform patients and their caregivers that the drowsiness associated with baclofen oral suspension use can be worsened by alcohol and other CNS depressants. Advise patients to read all medicine labels carefully, and to tell their healthcare provider about all prescription and nonprescription drugs they may use.

    Storage

    Instruct patients to store baclofen oral suspension at room temperature and to discard unused portion 2 months after first opening [see How Supplied/Storage and Handling (16.2)].


    Manufactured for:
    Slayback Pharma LLC,
    Princeton, NJ 08540.

    Manufactured at:
    Bora Pharmaceutical Services Inc
    7333 Mississauga Rd, Mississauga, 
    Ontario L5N 6L4, Canada (CAN)


    Revised: 12/2022

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC: 71225-140-01
    Rx Only

     

    Baclofen Oral Suspension

    25 mg per 5 mL
    (5 mg/mL)
    Concentrated Formulation


    250 mL

    ATTENTION: This is a concentrated baclofen formulation of 25 mg/5 mL (5 mg/mL).


    KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN

    Each mL contains 5 mg of baclofen USP

    Recommended Dosage: See prescribing information.

    Store at 20°C to 25°C (68°F to 77°F)
    excursions permitted from 15°C to 30°C (59°F to 86°F)
    [see USP Controlled Room Temperature].

    Date of first opening _______ / _______ / _______
    Discard unused portion 2 months after first opening.

    SHAKE BEFORE USING

    Baclofen Carton Label

  • INGREDIENTS AND APPEARANCE
    BACLOFEN 
    baclofen suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 71225-140
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    BACLOFEN (UNII: H789N3FKE8) (BACLOFEN - UNII:H789N3FKE8) BACLOFEN5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    XANTHAN GUM (UNII: TTV12P4NEE)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    Product Characteristics
    Color    Score    
    ShapeSize
    FlavorGRAPEImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 71225-140-011 in 1 CARTON06/19/2023
    1250 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21725206/19/2023
    Labeler - Slayback Pharma LLC (967770848)
    Establishment
    NameAddressID/FEIBusiness Operations
    Bora Pharmaceutical Services Inc205556368ANALYSIS(71225-140) , MANUFACTURE(71225-140) , PACK(71225-140)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.